Better Buy: Illumina, Inc. Vs. Intuitive Surgical, Inc.

Investors have bid up shares in Illumina (ILMN) and Intuitive Surgical (ISRG) to frothy levels in the past. With markets off their highs, is one a better buy than the other?

Apr 15, 2014 at 2:30PM

Health care investors have never been shy about rewarding innovation. Biotech companies continually sport nosebleed valuation based on assumptions that new, game-changing therapies will improve patient outcomes.

But biotech isn't the only health care industry reshaping patient treatment. Investors have bid up shares in genetic research equipment maker Illumina (NASDAQ:ILMN) and surgical robotics company Intuitive Surgical (NASDAQ:ISRG), too. Share prices in both companies have become less rich over the past few weeks, suggesting it's a good time to consider whether one is a better buy than the other.

ISRG Chart

ISRG data by YCharts.

Debating sales
Both companies are reimagining patient treatment. Illumina's gene sequencers are being used by commercial and non-profit research departments to identify intriguing new disease targets, while Intuitive's robotics are reshaping how doctors conduct complex surgery. 

In order to see whether their technology warrants higher multiples, investors should consider each company's revenue trend. If the sales are growing quickly, it's more likely margin will expand as unit volume is leveraged against fixed costs. 

Over at Intuitive, sales grew until 2013, but have since turned lower. Last week, Intuitive reported dismal preliminary first-quarter results showing that sales drooped 24% year over year because of sales of its da Vinci surgical system sliding 59%.

That may suggest that Intuitive has fully penetrated its target market. Or it may suggest buyers have been holding off on purchases in anticipation of Intuitive's latest product. The latter is possible given Intuitive announced earlier this month it is rolling out its latest generation system. The potential impact of this product was discussed by fellow Fools Michael Douglass and David Williamson in last week's Market Checkup

While Intuitive's sales are struggling, Illumina's revenue has been steadily growing thanks to rebounding R&D spending.

After Illumina's sales paused in 2011 and 2012 because of government cuts to health care research, researchers' pent-up demand is boosting results as budgets loosen. As a result, Illumina's sales totaled $387 million in the fourth quarter, up 25% from last year, bringing full-year sales to $1.42 billion, up 24% from 2012.

ISRG Revenue (TTM) Chart

ISRG Revenue (TTM) data by YCharts.

While both companies should be applauded for growing their sales significantly since 2010, growth only matters if it eventually turns into profit. 

Unfortunately, operating margin is retreating at both companies. Intuitive's margin has retreated from 40% to just shy of 38% because the company sold fewer systems, added headcount, and invested in its latest prototype.

Illumina's profit drop has been even more pronounced. The company is aggressively expanding its infrastructure in Asia to capitalize on China's growing research spend, and that's weighing on margins. Illumina believes those investments will pay off given China already accounts for 12% of its sales, and research spending in China is forecast to eclipse spending in the U.S. by 2022.

ISRG Operating Margin (TTM) Chart

ISRG Operating Margin (TTM) data by YCharts.

Debating valuation
Since Illumina has been growing quickly this past year, investors are paying more for future earnings than at any point in the past five years. Despite investors paying less for sales than they were two months ago, Illumina's forward P/E ratio remains north of 65.

By comparison, Intuitive looks like a relative bargain at 30 times next year's earnings, especially since the measure was above 50 just a few years ago. 

ISRG PE Ratio (Forward) Chart

ISRG P/E Ratio (Forward) data by YCharts.

Since earnings can be affected by accounting charges, another way to value these companies is to consider price to free cash flow, which shows how much operating cash is being generated by selling the company's products. 

Intuitive is trading at 23 times free cash, which may suggest there's an opportunity given this is at the low end of its five-year range. Illumina is trading at 63 times free cash, which is pretty pricey.

ISRG Price to Free Cash Flow (TTM) Chart

ISRG Price to Free Cash Flow (TTM) data by YCharts.

Fool-worthy final thoughts
Since growth stocks have  a better chance of generating bigger-than-expected profit than more mature, slower growing companies, they deserve a premium. In this case, Illumina's growth appears to justify the premium more than Intuitive.

However, betting that Intuitive's new product cycle is about to kick off another move higher in sales could pay off, but it comes with risk. Intuitive recently settled lawsuits tied to earlier versions of the da Vinci system and has admitted that more suits could be coming. If they don't, then sales of Intutive's new system should help pricing, boosting its already high margin, and delivering bigger profit to its bottom line. 

These 6 stocks are poised for incredible growth and may have fewer question marks
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his six carefully chosen picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Todd Campbell has no position in any stocks mentioned. He owns E.B.Capital Markets, LLC, whose clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC, whose clients do not have positions in the companies mentioned. The Motley Fool recommends Illumina and Intuitive Surgical. The Motley Fool owns shares of Intuitive Surgical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers